Exhibit 99.1

NEWS RELEASE for August 13, 2004

Contact: Michael Mason (investors)          Eric Friedman, CFO
         Allen & Caron Inc                  Integrated BioPharma Inc
         212 691 8087                       973 926 0816
         michaelm@allencaron.com            e.friedman@chemintl.com



                      Statement by Integrated BioPharma Inc


HILLSIDE,  N.J.,  Aug.  13 -  Integrated  BioPharma,  Inc.  (Amex:  INB - News)
said today that it knows of no fundamental reason for the recent decline of its
stock price.

INB Chief Executive Officer E. Gerald Kay stated, "The Company is in a healthy
and secure position, both financially and in terms of our business plan and
prospects. We recently shipped our first order of Paclitaxel API, the basis for
a variety of cancer chemotherapy treatments, from our Paxis Pharmaceuticals
subsidiary; it was produced under GMP (Good Manufacturing Practices) conditions
at our state-of-the-art plant in Boulder, Colorado, the largest such facility in
the country. We have a solid and robust balance sheet, with a recent financing
of $12.5 million, and our base nutraceutical business is generating cash and
profits."

About Integrated BioPharma Inc (INB)

INB serves the pharmaceutical, biotech and nutraceutical industries. Through
several wholly owned subsidiaries, INB develops, manufactures and distributes
more than 130 products worldwide. Its subsidiary, Paxis Pharmaceuticals, Inc.,
develops and operates a state-of-the-art GMP facility for the production and
sale of paclitaxel and related drugs. Through its biotech subsidiary, NuCycle
Therapy, Inc., INB is developing human therapeutics and preventive cancer
compounds in transgenic plants. Further information is available at
http://www.iBioPharma.com.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Such
statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. Further information on potential risk factors that could affect the
company's financial results can be found in the company's Reports filed with the
Securities and Exchange Commission.